The pharmaceutical company Hypera is expected to complete a significant portion of the working capital optimization strategy announced on Friday in the fourth quarter of this year, maintaining the adjustments until the end of 2025 when it expects to have an accounts receivable level of 60 days compared to 116 at the end of the first half of this year, said the company’s president, Breno de Oliveira, this Monday.
“It’s a very aggressive strategy on our part, but it can bring a lot of value to shareholders,” said the executive during a conference with analysts about the strategy announced after the market closed last Friday.
READ MORE: Owner of Buscopan, Coristina and Neosaldina discontinues projections for 2024
The company, which owns brands such as Buscopan, Coristina and Neosaldina, intends to achieve an increase in operating cash generation of R$2.5 billion by 2028 and R$7.5 billion over the next ten years.
According to Breno, the six-quarter plan will be implemented by reducing inventories at distributor customers, such as pharmacy chains, and reducing sales, which should impact margins in the short term.
“It will require a change in dynamics with our customers, but this is in line with competitors’ practices”, stated the executive president of Hypera.
The expectation is that, from 2026, with improvements in the company’s working capital, which during the pandemic was forced to work with high levels of stocks of inputs and products to deal with problems in logistics chains, net revenue will return growing within estimates prior to the implementation of the plan, said Oliveira.
“It is the best strategy in the medium and long term”, said the president of Hypera. “We will operate more efficiently and we see enormous potential for generating value for shareholders,” he added.
(By Alberto Alerigi Jr.)
